Sypharma Pty

Sypharma is an Australian specialty contract development manufacturing organization (CDMO) committed to creating healthier futures by developing, manufacturing, and marketing therapeutic goods. The company offers integrated CDMO services, guiding clients from concept to reality through comprehensive pharmaceutical development. Their experienced scientists focus on innovation, process agility, and production efficiency, delivering smarter outcomes. Sypharma's service offerings include new drug development, early-stage formulation, analytical development, scale-up, and process validation for commercial launch across various dosage forms. They also provide in-house analytical development and a release laboratory, upholding uncompromising quality and compliance from research and development through commercialization. Sypharma is accredited under international Good Manufacturing Practice (GMP) codes and operates under licenses from the Therapeutic Goods Administration (TGA), ISO13485 Medical Device, and the Australian Pesticides and Veterinary Medicines Authority (APVMA). They serve biotech professionals globally, offering support from early development to commercialization, and extend Australian R&D tax incentives to their clients.